p53基因突变与乳腺癌新辅助化疗疗效关系的研究
|
摘要
目的
抑癌基因p53与乳腺癌细胞生长、凋亡和耐药有密切联系。本实验将比较PCR-SSCP (聚合酶链反应-单链构象多态性)法与临床上常用的免疫组化法检测p53基因突变的结果是否一致,观察p53基因突变与乳腺癌常用临床病理指标的关系,并评估其与蒽环类及紫杉类为基础的新辅助化疗短期疗效的关系,初步探索其作为新辅助化疗疗效预测因子的可能性。
方法
本实验选取中南大学湘雅医院乳腺科2011年9月至2011年12月间初治的确诊为ⅡA、ⅡB及ⅢA期乳腺癌患者共65例为研究对象,随机行EC(表柔比星+环磷酰胺)、TC(多西他赛+环磷酰胺)或TAC(多西他赛+吡柔比星+环磷酰胺)方案新辅助化疗三周期,经外周血PCR-SSCP法和免疫组化法检测p53基因突变,并于第三周期化疗结束后使用触诊及B超评估治疗疗效。
结果
1.p53基因突变多见于乳腺癌临床分期ⅢA期、腋窝淋巴结转移阳性和ER表达阴性患者中(p值分别为0.047、0.032和0.036),而与患者年龄、绝经状况、肿瘤组织学分级、PgR、C-erbB2及Ki67表达无关。
2.分子亚型中,p53基因突变在三阴性亚型乳腺癌中较多见(9%),基因未突变在luminal B亚型中较多见(34%)(p=0.032)。
3. PCR-SSCP基因检测与免疫组化方法检测所得p53突变结果基本吻合(p<0.001),且一致性中等偏高(kappa=0.670)。
4.p53基因突变患者对EC、TC及TAC方案新辅助化疗均不敏感(p=0.62),未突变患者对TAC方案化疗较其他两种敏感(p=0.025)。
5.回归方程显示,乳腺癌新辅助化疗疗效与腋窝淋巴结转移、C-erbB2表达和p53基因突变有关,与年龄、月经状态、临床分期、PgR和Ki67表达无关(p<0.05)。其中ER和p53为保护因素(b<0)。
结论
1.p53基因突变多见于乳腺癌临床分期ⅢA期、腋窝淋巴结转移阳性和ER表达阴性患者中。分子亚型中,p53基因突变在三阴性亚型乳腺癌患者中较多见,而未突变在luminalB亚型患者中较多见。
2.p53基因突变患者对EC、TC及TAC方案新辅助化疗不敏感,未突变患者则对TAC方案新辅助化疗有较高的敏感性,可能为指导实际临床用药提供一定的理论依据。
3. PCR-SSCP方法与免疫组化法检测p53基因突变结果的一致性较高,且有一定的推广价值。
Objective
Tumor suppressor gene p53has been implicated in growth and apoptosis of breast tumor cells and resistance to chemotherapy. This study was performed to further access the differences between Immunohis-tochemistry(IHC), the most common way to detect p53gene mutation in clinical research, and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis in the inspection of p53mutation in breast cancer patients. In addition, we tried to figure out the relationship between the mutation and some clinical histologic indexes. Then, we had conducted the study of the prognostic value of p53mutation to chemotherapy response of anthracycline and taxanes, in order to evaluate the significance of the gene mutation for short term outcomes.
Method
Sixty-five patients with phase ⅡA, ⅡB and ⅢA breast cancer received neoadjuvant chemotherapy treatment of EC or TC or TAC scheme for three cycles. IHC and plasma PCR-SSCP were used to detect the mutation of p53gene while ultrasound was used to evaluate the effectiveness of neoadjuvant chemotherapy.
Result
1. Mutation of p53gene was directly relative to IIIA stage of TNM classification, metastasis of axillary nodes and negative of ER expression (p=0.047,0.032, and0.036), rather than age, menstrual condition, tumor histological grade, and expression of PgR, C-erbB2and Ki67.
2. Among molecular subclasses of breast cancer, p53gene mutation was more common in thiple-negative subtype (9%) while non-mutation in luminal B subtype (34%).
3. The result of PCR-SSCP was familiar with IHC in detecting p53gene mutation, and the similarity was high.
4. None of the tumors with p53mutation were response to EC, TC or TAC scheme. In the contract, tumors without p53mutation showed a good response to TAC scheme (p=0.025).
5. A significant correlation with neoadjuvant chemotherapy efficiency and axillary node metastasis, expression of ER, C-erbB2and p53mutation was found. Meantime, age, menstrual condition, TNM classification, and expression of PgR and Ki67were not correlation with the response to treatment (p<0.05). And ER and p53were regarded as protective factors of breast cancer (b<0).
Conclusion
1. Mutation of p53gene was directly relative to IIIA stage of TNM classification, metastasis of axillary nodes and negative of ER expression. Also, p53gene mutation was more common in thiple-negative subtype breast cancer, while non-mutation was in luminal B subtype.
2. None of the tumors with p53mutation were response to EC or TC or TAC scheme. In the contract, tumors without p53mutation showed a good response to TAC scheme, which might provide a guide for future clinical therapy.
3. PCR-SSCP analysis was just as the effective as IHC in detecting p53gene mutation.
抑癌基因p53与乳腺癌细胞生长、凋亡和耐药有密切联系。本实验将比较PCR-SSCP (聚合酶链反应-单链构象多态性)法与临床上常用的免疫组化法检测p53基因突变的结果是否一致,观察p53基因突变与乳腺癌常用临床病理指标的关系,并评估其与蒽环类及紫杉类为基础的新辅助化疗短期疗效的关系,初步探索其作为新辅助化疗疗效预测因子的可能性。
方法
本实验选取中南大学湘雅医院乳腺科2011年9月至2011年12月间初治的确诊为ⅡA、ⅡB及ⅢA期乳腺癌患者共65例为研究对象,随机行EC(表柔比星+环磷酰胺)、TC(多西他赛+环磷酰胺)或TAC(多西他赛+吡柔比星+环磷酰胺)方案新辅助化疗三周期,经外周血PCR-SSCP法和免疫组化法检测p53基因突变,并于第三周期化疗结束后使用触诊及B超评估治疗疗效。
结果
1.p53基因突变多见于乳腺癌临床分期ⅢA期、腋窝淋巴结转移阳性和ER表达阴性患者中(p值分别为0.047、0.032和0.036),而与患者年龄、绝经状况、肿瘤组织学分级、PgR、C-erbB2及Ki67表达无关。
2.分子亚型中,p53基因突变在三阴性亚型乳腺癌中较多见(9%),基因未突变在luminal B亚型中较多见(34%)(p=0.032)。
3. PCR-SSCP基因检测与免疫组化方法检测所得p53突变结果基本吻合(p<0.001),且一致性中等偏高(kappa=0.670)。
4.p53基因突变患者对EC、TC及TAC方案新辅助化疗均不敏感(p=0.62),未突变患者对TAC方案化疗较其他两种敏感(p=0.025)。
5.回归方程显示,乳腺癌新辅助化疗疗效与腋窝淋巴结转移、C-erbB2表达和p53基因突变有关,与年龄、月经状态、临床分期、PgR和Ki67表达无关(p<0.05)。其中ER和p53为保护因素(b<0)。
结论
1.p53基因突变多见于乳腺癌临床分期ⅢA期、腋窝淋巴结转移阳性和ER表达阴性患者中。分子亚型中,p53基因突变在三阴性亚型乳腺癌患者中较多见,而未突变在luminalB亚型患者中较多见。
2.p53基因突变患者对EC、TC及TAC方案新辅助化疗不敏感,未突变患者则对TAC方案新辅助化疗有较高的敏感性,可能为指导实际临床用药提供一定的理论依据。
3. PCR-SSCP方法与免疫组化法检测p53基因突变结果的一致性较高,且有一定的推广价值。
Objective
Tumor suppressor gene p53has been implicated in growth and apoptosis of breast tumor cells and resistance to chemotherapy. This study was performed to further access the differences between Immunohis-tochemistry(IHC), the most common way to detect p53gene mutation in clinical research, and polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) analysis in the inspection of p53mutation in breast cancer patients. In addition, we tried to figure out the relationship between the mutation and some clinical histologic indexes. Then, we had conducted the study of the prognostic value of p53mutation to chemotherapy response of anthracycline and taxanes, in order to evaluate the significance of the gene mutation for short term outcomes.
Method
Sixty-five patients with phase ⅡA, ⅡB and ⅢA breast cancer received neoadjuvant chemotherapy treatment of EC or TC or TAC scheme for three cycles. IHC and plasma PCR-SSCP were used to detect the mutation of p53gene while ultrasound was used to evaluate the effectiveness of neoadjuvant chemotherapy.
Result
1. Mutation of p53gene was directly relative to IIIA stage of TNM classification, metastasis of axillary nodes and negative of ER expression (p=0.047,0.032, and0.036), rather than age, menstrual condition, tumor histological grade, and expression of PgR, C-erbB2and Ki67.
2. Among molecular subclasses of breast cancer, p53gene mutation was more common in thiple-negative subtype (9%) while non-mutation in luminal B subtype (34%).
3. The result of PCR-SSCP was familiar with IHC in detecting p53gene mutation, and the similarity was high.
4. None of the tumors with p53mutation were response to EC, TC or TAC scheme. In the contract, tumors without p53mutation showed a good response to TAC scheme (p=0.025).
5. A significant correlation with neoadjuvant chemotherapy efficiency and axillary node metastasis, expression of ER, C-erbB2and p53mutation was found. Meantime, age, menstrual condition, TNM classification, and expression of PgR and Ki67were not correlation with the response to treatment (p<0.05). And ER and p53were regarded as protective factors of breast cancer (b<0).
Conclusion
1. Mutation of p53gene was directly relative to IIIA stage of TNM classification, metastasis of axillary nodes and negative of ER expression. Also, p53gene mutation was more common in thiple-negative subtype breast cancer, while non-mutation was in luminal B subtype.
2. None of the tumors with p53mutation were response to EC or TC or TAC scheme. In the contract, tumors without p53mutation showed a good response to TAC scheme, which might provide a guide for future clinical therapy.
3. PCR-SSCP analysis was just as the effective as IHC in detecting p53gene mutation.
引文
[1]Lvkovic-Kapicl T, Knezevic-Usaj S, Panjkovic M, et al. The influence of aging on pathologic and immunobiologic parameters of invasive ductal breast carcinoma. [J] Vojnosanit Pregl,2006,63(11):921-927
[2]Kaufmann M, von Minckwitz G, Smith R, et al. International expertpanel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. [J] Clin Oncol 2003,21:2600-2608
[3]杨海松,黄建军,毛大华等.新辅助化疗对乳腺癌雌激素受体和P53基因及人表皮生长因子受体-2的影响及意义,[J]论著,2011,4：1292-1295
[4]曹茵,张爱玲.不同新辅助化疗方案治疗局部晚期乳腺癌的疗效比较,[J]实用预防医学,2006,13(1)：68-69
[5]Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. [J] Lancet 2003,32:362-369
[6]Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. [J] Clin Oncol 2006,24:4236-4344
[7]成秀梅.肿瘤抑制基因p53的研究进展.[J]现代诊断与治疗,2008,19(3)：158-160
[8]Turner N, Tutt A, Ashworth A, et al. Hallmarks of BRCAness'in sporadic cancers[J]. Nat Rev Cancer,2004,4(10):814
[9]马楠,庞达,薛英威,P53基因与乳腺癌的关系及研究进展,[J]黑龙江医学,2001,10(25)：725-726.
[10]陈青,p53基因和乳腺癌的相关性研究进展,[J]实验与检验医学,2011,29(1)：57-59
[11]Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoisomerase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy [J]. Cancer Res,2009,69(24):705-709
[12]Teodoro JG, Parker AE, Zhu X, et al. p53-mediated inhibition of angiogenesis through up regulation of a collagen proly hydroxylase [J]. Science, 2006,3(13):968-971
[13]Teodoro JG, Evans SK, Green MR, et al. Inhibition of tumor angiogenesis by p53; a new role for the guardian of the genome [J]. J Mol Med, 2007,85(11):1175-1186
[14]Kamangar F, Dores GM, Anderson WF, et al. Patterns of cancer incidence, mortality, and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world [J]. Clin Oncol, 2006,24(14):2137-2143
[15]Norberg T, Klaar S, Karf G, et al. Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort [J].Cancer Res, 2001,61(22):8317-8321
[16]Mottolese M, Dadasi EA, Botti C, et al. Phenotypic changes of p53 Her2,and Fas system in multiple normal tissues surrounding breast cancer[J]. Cell Physiol,2005,204(1):106-112
[17]Marie Stenmark Askmalm, John Carstensen, Bo Nordenskjold, et al. Mutation and Accumulation of p53 Related to Results of Adjuvant Therapy of Postmenopausal Breast Cancer Patients, [J] Acta Oncologica, 2004,43(3):235-244
[18]D. P. Korkolis, E. T.Soll, Not p53, Her2-neuor Cathepsin-D Expression are Independent Prognostic Factors in Breast Cancer Patients. [J]Anticancer research 24:2061-2068 (2004)
[19]Helen H, Chen W, Su W, et al. p53 and CerbB-2 but not bcl2 are predictive of metastasis free survival in breast cancer patients receiving post mastectomy ad juvant radiotherapy in Taiwan. [J] Clin Oncol,2002,32(9):332-339
[20]李惠平,贾廷珍,p53过表达可作为中国乳腺癌妇女的独立预后危险因素2005上海国际乳腺癌暨第八届全国乳腺癌会议论文汇编[C].2005,60：25-27
[21]Bianchi S, Calzolari A, Vezzosi V,et al. Lack of prognostic value of p53 protein expression in node-negative breast cancer. [J] Tumori 1997,83(3):669-672
[22]Gohring UJ, Scharl A, Heckel C, et al. p53 protein in 204 patients with primary breast carcinma immunohistochemical detection and clinical value as a prognostic factor. [J] Arch Gynecol Obstet 1995,256(3):139-146
[23]Elledge RM, Allred GD. Prognostic and predictive value of p53 and p21 in breast cancer. [J] Breast Cancer Res Treatment 1998,52:79-98
[24]Hartmann A, Blaszyk H, Kovach JS,et al. The molecular epidemiology of p53 gene mutations in human breast cancer. [J] Trends Genet 1997,13(1):27-33
[25]Pharoah PD, Day NE, Caldas C, et al. Somatic mutations in thep53 gene and prognosis in breast cancer:a meta-analysis. [J] Breast Cancer 1999,80(12): 1968-1973
[26]Chiarugi V, Magnelli L, Cinelli M,et al. Role of p53 mutations in the radio sensitivity status of tumor cells. [J]Tumori 1998,84:517-520
[27]Bottini A, Berruti A, Bersiga A et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.[J] Clin Cancer Res 2000,6:2751-2758
[28]Electra Paskett, James Herndon, Kathleen Donohue, et al. Health-related quality of life in long-term breast cancer survivors:differences by adjuvant chemotherapy dose in CALGB study 8541. [J]Cancer.2009,115(5):1109-1120
[29]Kandioler-Eckersberger D, Ludwig C, Dudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. [J]Clin Cancer Res 2000,6:50-56
[30]Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basa-llike breast cancer. [J]Proc Natl Acad Sci USA 2007,104:12111-12116
[31]Andre F, Pusztai L. Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. [J]Pharm Res 2006,23:1951-1958
[32]Garber JE, Richardson A, Harris LN et al. Neoadjuvant cisplatin in triple-negative breast cancer. [C] San Antonio Breast Cancer Symposium Poster 2006,3074-3079
[33]Geisler S, LningP E, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. [J]Cancer Res 2001,61:2505-2512
[34]Aas T, Hall PA, McCluggage, WG, et al. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. [J] Pathol.2006,208:1-6
[35]Atha D, Wenz HM, Morehead H, et al. Detection of p53 point mutations by single strand conformation polymorphism (SSCP):analysis by capillary electrophoresis. [J] Electrophoresis 1998,19:172-179
[36]Peter A Fasching, Katharina Heusinger, Lothar Haeberle, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. [J] BMC Cancer,2011,11:486-492.
[37]AnelliA, B rentani RR, Gadeha AP, Correlat ion of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage B breast cancer [J] Ann Onco,2003,14 (3):428-432
[38]Lacroix M, Toillon RA, Leclercq G,et al. p53 and breast cancer, an update. [J]Endocr Relat Cancer.2006; 13:293-325
[39]Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistoche-mistry. [J] Natl Cancer Int 1996,88:173-182
[40]Kandel RA, Li S-Q, Ozcelik H, Rohan TE, et al. p53 protein accumulation and mutations in normal and benign breast tissue. [J] Cancer 2000,87:73-78
[41]Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. [J] Nat Rev Cancer 2004,4:793-805
[42]Jap E, McGee J. Nonisotopic SSCP detection in PCR products by ethidium bromide staining. [J] Trends Genet 1992,8:49-55
[43]肖晓光,王晶,刘新元,应用PCR-SSCP法检测乳腺癌患者血中p53基因突变,[J]大连医科大学学报,2006,28(5)：414-420
[44]Zhi Ming Shao, Jun Wu, Zhen Zhou Shen, p53 Mutation in Plasma DNA and Its Prognostic Value in Breast Cancer Patients, [J]Clin Cancer Res 2001,7: 2222-2227
[45]Fournie GJ, Courti n JP, Laval F,et al. Plasma DNA as a marker of cancerous cell deat h; i nvestgation i n patients suffering fromlung cancer and i n nude mice beari ng human tumor. [J]Cancer Lett,1995,91(2):221-227
[46]Anker, P, Lefort, F, Vasioukhin, V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. [J]Gastroenterology,1997,112:1114-1120
[47]Silva, J M, Gonzalez, R, Dominguez, G,et al.TP53 gene mutations in plasma DNA of cancer patients. [J] Genes Chromosomes Cancer,1999,24:160-161
[48]Hagen Blaszyk, Hartmann, Julie M, et al. A Prospective trial of midwest breast cancer patients:a p53 gene mutation is the most important predictor of adverse outcome; [J] Cancer (Pred. Oncol.):2000,89,32-38
[49]D. Korkolise, E. T Soli, D. Fouskakis, et al.Tumor Histology and Stage but Not p53, Her2-neuor Cathepsin-D Expression are Independent Prognostic Factors in Breast Cancer Patients; [J]anticancer reseach.2004,24:2061-2068
[50]张勤,TopoIla、P53蛋白在不同分子亚型乳腺癌中的表达及其预后价值的研究,2011年天津大学硕士学位论文
[51]Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. [J] Natl Cancer Inst.2006, 98:911-919
[52]Nicolini A, Carpi A, Tarro G, et al. Biomolecular markers of breast cancer. [J]Front Biosci.2006,11:1818-1843
[53]Linjawi A, Kontogiannea M, Halwani F, et al. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. [J] Am Coll Surg.2004, 198:83-90
[54]Hlupic L, Jakic-Razumovic J, Bozikov J, et al. Prognostic value of different factors in breast carcinoma. [J]Tumori.2004,90:112-119
[55]Dimitrakakis C, Konstadoulakis M, Messaris E, et al. Molecular markers in breast cancer:can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? [J] Breast.2004,11:279-285
[56]林奇,慧玉,刘洋等,新辅助化疗对乳腺癌患者survivin、Ki-67、ER、 C-erbB-2、p53和肿瘤组织学分级的影响及其疗效预测意义,[J]实用肿瘤杂志,2010,4(25)：400—404
[57]Faney te IF, Schrama JG, Peterse JL, Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome. [J] Breast Cancer,2003,88(3):406-412
[58]Mieog JS, H age JA, V ijuerM J, et a.l Tumouer response to preoperative anthracycline-based chemotherapy in operable breast cancer:the predictive role of p53 expression.[J] Eur J Cancer,2006,42(10):1369-1379
[59]Geisler S B, rressen Dale AL,Johnsen H, et al. TP53 gene mutations predict the reponse to neoadjuvant treatment with 5-flurouracil and mitomycin in locally advanced breast cancer. [J]Clin Cancer Res,2003,9(15):5582-5588
[60]Bidard FC, Matthieu MC,Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. [J] Ann Oncol 2008,19(7):1261-1265
[61]Clahsen PC, van de Velde CJH, Duval C et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. [J] Clin Oncol 1998,16:470-479
[62]Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. [J]Clin Cancer Res 2000,6:50-56
[1]Kaufmann M, von Minckwitz G, Smith R,et al. International expertpanel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. [J] Clin Oncol 2003,21:2600-2608
[2]Smith IE. Preoperative/neoadjuvant medical therapy for early breast cancer. [J]Lancet Oncol 2001,2:561-570
[3]Fisher B, Bryam J, Wolmark N, et al. Effect Of preoperative chemotherapy on the outcome of women with operable breast cancer, [J] Clin Oncol 1998,16:2672-2685
[4]吕新生,乳腺癌的新辅助化疗,[J]中国普通外科杂志,2006,15(10)：721-724
[5]Chuthapisith S,Eremin JM,et al. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer:chemoresistance and prediction of response to drug therapy. [J] Surgeon.2006,4(4):211-219
[6]Jae K. Lee, Charles Coutant, Young-Chul Kim,et al. Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. [J] Clin Cancer Res 2010,16:711-718
[7]Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. [J] Clin Oncol 1998,16: 2672-2685
[8]李书玲,乳腺肿瘤学[M].北京：科学技术文献出版社,2000：379-433
[9]杨接辉.CTF方案在乳腺癌新辅助化疗近期的疗效观察.[J]中国综合临床,2004,20(7)：629—630
[10]Van der JA, vandevelde cJ, Julien JP, et al. Preoperative chemotheapy in primary operable breaSt cancer:results from the Eumpean Organization for Research and Treatment of cancer trial 10902. [J] clinical,2001,19(22): 4224-4237
[11]Vlastos G, Mirza N Q, Lenert J T,et al. The feasibility of minimally invasive surgery for stage ⅡA, IIB, andⅢA breast carcinoma patients after tumor downstaging with induction chemotherapy. [J]Cancer,2000,88:1417-1424
[12]Newman L A, Buzdar A U, Singletary S E, et al.A prospective trial of preoperative chemotherapy in resectable breast cancer:predictors of breast-conservation therapy feasibility. [J] Ann Surg Oncol,2002,9:228-234
[13]Baslaim M M, Malik A, Sobhi S, et al.Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. [J]Am J Surg,2002,184:299-230
[14]陈伟光,李梅,李艳薇等,多西他赛联合毗柔比星的新辅助化疗方案治疗乳腺癌的临床观察,[J]实用医学杂志,2009,25(10)：1672-1673
[15]Chaffare H, Limongelli S, Pumshotham A D,et al. Neoadjuvant chemotherapyin breast cancer. [J]Br J Surg,2005,92(-):14-23
[16]Trudeau M and Pagani O. Epirubicin in combination with the taxanes. [J]Seminars in oncology 2001,28(12):41-50
[17]Kenneth Villman. A phase Ⅱ study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer, [J] European Journal of Cancer.2007,43(7):1153-1160
[18]Bear HD,Anderson S,Smith RE,et al.Sequential preoperative or postoperative docetaxel added to preperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. [J]J Clin Oncol,2006,24:2019-2027
[19]曹茵,张爱玲,不同新辅助化疗方案治疗局部晚期乳腺癌的疗效比较,[J]实用预防医学.2006,13(1)：68-69
[20]Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer:a trial of two doses by 3 hour infusion in patients with disease recurrence after prior therapy with anthracyclines. [J] Natl Cancer Inst 1995,87:1169-1175
[21]Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of Paclitaxel in patients with metastatic breast cancer. [J] J Clin Oncol 1996,14:1858-1867
[22]Seidman AD, Barrett S, Hudis C, et al. Three hour Taxol infusion as intitial and as salvage chemotherapy of metastatic breast cancer. [J] Proc Am Soc Clin Oncol 1994,13:A65
[23]Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase Ⅱ study of Paclitaxel in advanced brease cancer resistant to anthracyclines. [J] Eur J Cancer 1996,32:47-51
[24]Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer:a phase Ⅱ trial of the EORTC-CSG. [J] J Clin Oncol,1995,13:314-322,
[25]Tubiana-Hulin, M Dieras, V Fumoleau, et al. Phase Ⅱ trial combining docetaxel and doxorubicine in the neoadjuvant setting in patients with operable breast carcinoma:final results. [J] Breast Cancer Res. Treat.,2000,64:250-258
[26]Valero V, Esteva FJ, SahinA,et al. Phase Ⅱ trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy tamoxifen in locally advanced breast cancer. [J] Breast Cancer Res. Treat.2000,64:253-260
[27]Luporsi, E, Vanlemmens, L, Coudert, B,et al. Six cycles of FEC 100 versus 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients:preliminary results of a randomized Phase Ⅱ trial of Girec S01. Proc. Am. Soc. [J] Clin. Oncol,2000,19:355-362
[28]Wenzel C., Locker G. J, Schmidinger M., et al. Combined analysis of two Phase Ⅱ trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel-granulocyte colony stimulating factor. [J] Anticancer Drugs,2002,13:1-8
[29]E. Espinosa, S Morales,et al. Docetaxel and high-dose epirubicin as neodajuvant chemotherapy in locally advanced breast cancer. [J] Cancer chemotherapy and pharmacology.2003,54(6):546-552
[30]胡薇,施俊义,吡柔比星或表柔比星联合紫杉醇新辅助化疗治疗局部晚期乳腺癌的随机对照研究,[J]第二军医大学学报,2010,31(1)：70-73
[31]Honkoop AH,Luykx de Bakker SA,Hoekman K,et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. [J]Oncolo-gist,1999,4:106-111
[32]Harbeck N, Beck T,et al. Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2 Overexpressing Breast Cancer:Results From the TECHNO Trial of the AGO and GBG Study Groups, [J] Clin Oncol. 2011,1; 29(25):3351-3357
[33]Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. [J]Cancer Res 2000,46:2578-2581
[34]I F Faneyte, J G Schrama, et al. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome, [J] Br J Cancer. 2003,88(3):406-412
[35]Keune JD, Jeffe DB, et al. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer, [J]Am J Surg.2010,199(4):477-484
[36]Vinnicombe SJ, MacVicar AD, Guy RL, et al. Primary breast cancer: Mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. [J] Radiology 1996,198:333-340
[37]Yeh E, Slanetz P, Kopans SB, et al.Prospective comparing of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. [J]Am J Roentgenol,2005,184:868-877
[38]张斌,张强,赵林等.乳腺癌新辅助化疗疗效的评价及影响因素分析[J]中华肿瘤杂志,2006,28：867-870
[39]Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. [J] AJR Am J Roentgenol.2002,179(5):1193-1199
[40]Belli P, Costantini M, Malaspina C,et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. [J]Clin Radiol.2006,61(11):946-953.
[41]Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. [J] Breast Cancer Res Treat 2008,108:183-90
[42]Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-FU, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer:an update of the initial randomized study population and data of additional patients treated with the same regimen. [J] Clin Cancer Res 2007,13:228-33
[43]Michiels S, Koscielny S, Hill C, et al. Prediction of cancer outcome with microarrays:a multiple random validation strategy. Lancet 2005,365:488-92
[44]Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiation:Guidelines of the American Society of Clinical Oncology. [J] Clin Oncol,2001,19:1539-1569,
[45]Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcomes of women with operable breast cancer. [J]Clin Oncol 1998,16:2672-2685
[46]Whelan TJ, Julian J, Wright J, et al. Does local-regional radiation therapy improve survival in breast cancer? A meta-analysis. [J] Clin Oncol 2000,18: 1220-1229
[47]De Steene JV, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival:The missing link. [J] Radiother Oncol 2000,55:263-272
[48]Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. [J] Int J Radiat Oncol Biol Phys 1999,44: 989-990
[49]Zeina Nahleh, Neoadjuvant chemotherapy for "Triple Negative" breast cancer:a review of current practice and future outlook, Medical Oncology.2001,27, (2):531-539
[50]Cornelia Liedtke, Chafika Mazouni, Kenneth R, et al. Hess, Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, [J] J Clin Oncol 2008,26(8):1275-1281
[51]Von Minckwitz, G.Kaufmann, M.Kummel,et al, Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane+/-trastuzumab containing chemotherapy. [C] San Antonio Breast Cancer Symposium, San Antonio,2008,79-83
[52]Carey, L.A., Perou, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. [J] Cancer research,2006,295,2492-2502
[53]Kassam, F., Enright, K., Dent, R., et al.Survival outcomes for patients with metastatic triple-negative breast cancer:implications for clinical practice and trial design. [J] Clin. Breast Cancer.2009.9:29-33
[54]Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab:a Brown University Oncology Group Study. [J] J Clin Oncol.2009,27:4693-4700
[55]Frasci G, Cornella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. [J]Ann Oncol.2009,20:1185-1192.
[56]齐小伟.三阴性乳腺癌患者的新辅助化疗疗效及生存分析.[J]中华乳腺病杂志.2009,3(1)：109-112
[57]Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. [J] Lancet 2003,362:362-369
[58]Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. [J] J Clin Oncol 2006,24: 4236-4244
[59]Macgrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma:Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST. [J]Br J Cancer, 1996,74:1458-1465
[60]Ogston KN, Miller ID, Schofield AC, et al. Can patients'likelihood of benefiting fromprimary chemotherapy for breast cancer be predicted before commencement of treatment? [J]Breast Cancer Res Treat,2004,86:181-189
[61]Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy. [J] Breast 2008,17:523-527
[62]Neubauer H, Gall C, Vogel U, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). [J] Anticancer Res 2008,28: 1797-1804
[63]T Hirata, C Shimizu,et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer, [J] British Journal of Cancer, 2009(101):1529-1536
[64]Jukkola A, Bloigu R, Soini Y, et al.C-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. [J] Eur J Cancer,2001,37(3):347-354
[65]Nigo YI, Yamashita M, Hirahara K, et al. Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function. [J] Proc Natl Acad Sci USA,2006,103(7):2286-2291
[66]Gregory RK, Pourles TJ, Salter J, et al.Prognoatic relevance of CerbB-2 express following neoadjuvant chemotherapy in patients in a randomized trial of neoadjvant versus adjuvant chemoendocrine therapy. [J] Breast Cancer Res Treat,2000,59(2):171-175
[67]Pritchard KI, Seperherd LE, O'Malley FP, et al. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. [J] N England J Med, 2006,354:2103-2014
[68]DiGiovanna MP, Stem DF, Edgenton S,et el. Influence of activation state of ErbB-2(HER-2)on response to adjuvant cyciophesphamide, doxorubiein, and fluoronraeii for stage II, node-positive breast cancer:study 8541 from the Cancer and Leukemia Group B. [J] J Clin Oncol,2008,26(14):2364-2372
[69]林其声,施雄文,徐书楷等,新辅助化疗对乳腺癌ki67、cox-2、p53表达的影响及其临床意义,[J]中国当代医药,2009,16(24)：13-14
[70]Mieog JS, H age JA, V ijuerM J, et a.l Tumouer response to preoperative anthracycline-based chemotherapy in operable breast cancer:the predictive role of p53 express ion. [J] Eur J Cancer,2006,42(10):1369-1379
[71]AnelliA, B ren tan iRR, Gad eha AP,et al. Correlat ion of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage, breast cancer. [J]Ann Onco,2003,14 (3):428-432
[72]Hagen Blaszyk, Hartmann,, Julie M, et al. A Prospective trial of midwest breast cancer patients:a p53 gene mutation is the most important predictor of adverse outcome. [J] Int. J. Cancer (Pred. Oncol.):2000,89,32-38
[73]Kandioler-Eckersberger D, Ludwig C, Dudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. [J] Clin Cancer Res 2000,6:50-56
[74]Nishiimura R, Osako T, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. [J] Breast Cancer.2010,17(4):269-275
[75]I F Faneyte, J G Schrama, et al. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome, [J]Br J Cancer. 2003 Feb 10;88(3):406-412
[76]T Petit, M Witt,et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase Ⅱ alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. [J] European Journal of Cancer, January 2004,40(2):205-211
[77]Gaber J, Richardsm A, Hanis LN, et al. Neoadjuvant cisphain (CDDP) in "triple-negative" breast cancer. [J] Breast Cancer Res Treat,2006,100(1):202
[2]Kaufmann M, von Minckwitz G, Smith R, et al. International expertpanel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. [J] Clin Oncol 2003,21:2600-2608
[3]杨海松,黄建军,毛大华等.新辅助化疗对乳腺癌雌激素受体和P53基因及人表皮生长因子受体-2的影响及意义,[J]论著,2011,4：1292-1295
[4]曹茵,张爱玲.不同新辅助化疗方案治疗局部晚期乳腺癌的疗效比较,[J]实用预防医学,2006,13(1)：68-69
[5]Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. [J] Lancet 2003,32:362-369
[6]Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. [J] Clin Oncol 2006,24:4236-4344
[7]成秀梅.肿瘤抑制基因p53的研究进展.[J]现代诊断与治疗,2008,19(3)：158-160
[8]Turner N, Tutt A, Ashworth A, et al. Hallmarks of BRCAness'in sporadic cancers[J]. Nat Rev Cancer,2004,4(10):814
[9]马楠,庞达,薛英威,P53基因与乳腺癌的关系及研究进展,[J]黑龙江医学,2001,10(25)：725-726.
[10]陈青,p53基因和乳腺癌的相关性研究进展,[J]实验与检验医学,2011,29(1)：57-59
[11]Di Leo A, Isola J, Piette F, et al. A meta-analysis of phase Ⅲ trials evaluating the predictive value of HER2 and topoisomerase Ⅱ alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy [J]. Cancer Res,2009,69(24):705-709
[12]Teodoro JG, Parker AE, Zhu X, et al. p53-mediated inhibition of angiogenesis through up regulation of a collagen proly hydroxylase [J]. Science, 2006,3(13):968-971
[13]Teodoro JG, Evans SK, Green MR, et al. Inhibition of tumor angiogenesis by p53; a new role for the guardian of the genome [J]. J Mol Med, 2007,85(11):1175-1186
[14]Kamangar F, Dores GM, Anderson WF, et al. Patterns of cancer incidence, mortality, and prevalence across five continents:defining priorities to reduce cancer disparities in different geographic regions of the world [J]. Clin Oncol, 2006,24(14):2137-2143
[15]Norberg T, Klaar S, Karf G, et al. Increased p53 mutation frequency during tumor progression-results from a breast cancer cohort [J].Cancer Res, 2001,61(22):8317-8321
[16]Mottolese M, Dadasi EA, Botti C, et al. Phenotypic changes of p53 Her2,and Fas system in multiple normal tissues surrounding breast cancer[J]. Cell Physiol,2005,204(1):106-112
[17]Marie Stenmark Askmalm, John Carstensen, Bo Nordenskjold, et al. Mutation and Accumulation of p53 Related to Results of Adjuvant Therapy of Postmenopausal Breast Cancer Patients, [J] Acta Oncologica, 2004,43(3):235-244
[18]D. P. Korkolis, E. T.Soll, Not p53, Her2-neuor Cathepsin-D Expression are Independent Prognostic Factors in Breast Cancer Patients. [J]Anticancer research 24:2061-2068 (2004)
[19]Helen H, Chen W, Su W, et al. p53 and CerbB-2 but not bcl2 are predictive of metastasis free survival in breast cancer patients receiving post mastectomy ad juvant radiotherapy in Taiwan. [J] Clin Oncol,2002,32(9):332-339
[20]李惠平,贾廷珍,p53过表达可作为中国乳腺癌妇女的独立预后危险因素2005上海国际乳腺癌暨第八届全国乳腺癌会议论文汇编[C].2005,60：25-27
[21]Bianchi S, Calzolari A, Vezzosi V,et al. Lack of prognostic value of p53 protein expression in node-negative breast cancer. [J] Tumori 1997,83(3):669-672
[22]Gohring UJ, Scharl A, Heckel C, et al. p53 protein in 204 patients with primary breast carcinma immunohistochemical detection and clinical value as a prognostic factor. [J] Arch Gynecol Obstet 1995,256(3):139-146
[23]Elledge RM, Allred GD. Prognostic and predictive value of p53 and p21 in breast cancer. [J] Breast Cancer Res Treatment 1998,52:79-98
[24]Hartmann A, Blaszyk H, Kovach JS,et al. The molecular epidemiology of p53 gene mutations in human breast cancer. [J] Trends Genet 1997,13(1):27-33
[25]Pharoah PD, Day NE, Caldas C, et al. Somatic mutations in thep53 gene and prognosis in breast cancer:a meta-analysis. [J] Breast Cancer 1999,80(12): 1968-1973
[26]Chiarugi V, Magnelli L, Cinelli M,et al. Role of p53 mutations in the radio sensitivity status of tumor cells. [J]Tumori 1998,84:517-520
[27]Bottini A, Berruti A, Bersiga A et al. p53 but not bcl-2 immunostaining is predictive of poor clinical complete response to primary chemotherapy in breast cancer patients.[J] Clin Cancer Res 2000,6:2751-2758
[28]Electra Paskett, James Herndon, Kathleen Donohue, et al. Health-related quality of life in long-term breast cancer survivors:differences by adjuvant chemotherapy dose in CALGB study 8541. [J]Cancer.2009,115(5):1109-1120
[29]Kandioler-Eckersberger D, Ludwig C, Dudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. [J]Clin Cancer Res 2000,6:50-56
[30]Liu X, Holstege H, van der Gulden H et al. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basa-llike breast cancer. [J]Proc Natl Acad Sci USA 2007,104:12111-12116
[31]Andre F, Pusztai L. Heterogeneity of breast cancer among patients and implications for patient selection for adjuvant chemotherapy. [J]Pharm Res 2006,23:1951-1958
[32]Garber JE, Richardson A, Harris LN et al. Neoadjuvant cisplatin in triple-negative breast cancer. [C] San Antonio Breast Cancer Symposium Poster 2006,3074-3079
[33]Geisler S, LningP E, Aas T, et al. Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. [J]Cancer Res 2001,61:2505-2512
[34]Aas T, Hall PA, McCluggage, WG, et al. Assessing p53 in clinical contexts: unlearned lessons and new perspectives. [J] Pathol.2006,208:1-6
[35]Atha D, Wenz HM, Morehead H, et al. Detection of p53 point mutations by single strand conformation polymorphism (SSCP):analysis by capillary electrophoresis. [J] Electrophoresis 1998,19:172-179
[36]Peter A Fasching, Katharina Heusinger, Lothar Haeberle, et al. Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment. [J] BMC Cancer,2011,11:486-492.
[37]AnelliA, B rentani RR, Gadeha AP, Correlat ion of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage B breast cancer [J] Ann Onco,2003,14 (3):428-432
[38]Lacroix M, Toillon RA, Leclercq G,et al. p53 and breast cancer, an update. [J]Endocr Relat Cancer.2006; 13:293-325
[39]Sjogren S, Inganas M, Norberg T, et al. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistoche-mistry. [J] Natl Cancer Int 1996,88:173-182
[40]Kandel RA, Li S-Q, Ozcelik H, Rohan TE, et al. p53 protein accumulation and mutations in normal and benign breast tissue. [J] Cancer 2000,87:73-78
[41]Bode AM, Dong Z. Post-translational modification of p53 in tumorigenesis. [J] Nat Rev Cancer 2004,4:793-805
[42]Jap E, McGee J. Nonisotopic SSCP detection in PCR products by ethidium bromide staining. [J] Trends Genet 1992,8:49-55
[43]肖晓光,王晶,刘新元,应用PCR-SSCP法检测乳腺癌患者血中p53基因突变,[J]大连医科大学学报,2006,28(5)：414-420
[44]Zhi Ming Shao, Jun Wu, Zhen Zhou Shen, p53 Mutation in Plasma DNA and Its Prognostic Value in Breast Cancer Patients, [J]Clin Cancer Res 2001,7: 2222-2227
[45]Fournie GJ, Courti n JP, Laval F,et al. Plasma DNA as a marker of cancerous cell deat h; i nvestgation i n patients suffering fromlung cancer and i n nude mice beari ng human tumor. [J]Cancer Lett,1995,91(2):221-227
[46]Anker, P, Lefort, F, Vasioukhin, V, et al. K-ras mutations are found in DNA extracted from the plasma of patients with colorectal cancer. [J]Gastroenterology,1997,112:1114-1120
[47]Silva, J M, Gonzalez, R, Dominguez, G,et al.TP53 gene mutations in plasma DNA of cancer patients. [J] Genes Chromosomes Cancer,1999,24:160-161
[48]Hagen Blaszyk, Hartmann, Julie M, et al. A Prospective trial of midwest breast cancer patients:a p53 gene mutation is the most important predictor of adverse outcome; [J] Cancer (Pred. Oncol.):2000,89,32-38
[49]D. Korkolise, E. T Soli, D. Fouskakis, et al.Tumor Histology and Stage but Not p53, Her2-neuor Cathepsin-D Expression are Independent Prognostic Factors in Breast Cancer Patients; [J]anticancer reseach.2004,24:2061-2068
[50]张勤,TopoIla、P53蛋白在不同分子亚型乳腺癌中的表达及其预后价值的研究,2011年天津大学硕士学位论文
[51]Boersma BJ, Howe TM, Goodman JE, et al. Association of breast cancer outcome with status of p53 and MDM2 SNP309. [J] Natl Cancer Inst.2006, 98:911-919
[52]Nicolini A, Carpi A, Tarro G, et al. Biomolecular markers of breast cancer. [J]Front Biosci.2006,11:1818-1843
[53]Linjawi A, Kontogiannea M, Halwani F, et al. Prognostic significance of p53, bcl-2, and Bax expression in early breast cancer. [J] Am Coll Surg.2004, 198:83-90
[54]Hlupic L, Jakic-Razumovic J, Bozikov J, et al. Prognostic value of different factors in breast carcinoma. [J]Tumori.2004,90:112-119
[55]Dimitrakakis C, Konstadoulakis M, Messaris E, et al. Molecular markers in breast cancer:can we use c-erbB-2, p53, bcl-2 and bax gene expression as prognostic factors? [J] Breast.2004,11:279-285
[56]林奇,慧玉,刘洋等,新辅助化疗对乳腺癌患者survivin、Ki-67、ER、 C-erbB-2、p53和肿瘤组织学分级的影响及其疗效预测意义,[J]实用肿瘤杂志,2010,4(25)：400—404
[57]Faney te IF, Schrama JG, Peterse JL, Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome. [J] Breast Cancer,2003,88(3):406-412
[58]Mieog JS, H age JA, V ijuerM J, et a.l Tumouer response to preoperative anthracycline-based chemotherapy in operable breast cancer:the predictive role of p53 expression.[J] Eur J Cancer,2006,42(10):1369-1379
[59]Geisler S B, rressen Dale AL,Johnsen H, et al. TP53 gene mutations predict the reponse to neoadjuvant treatment with 5-flurouracil and mitomycin in locally advanced breast cancer. [J]Clin Cancer Res,2003,9(15):5582-5588
[60]Bidard FC, Matthieu MC,Chollet P, et al. p53 status and efficacy of primary anthracyclines/alkylating agent-based regimen according to breast cancer molecular classes. [J] Ann Oncol 2008,19(7):1261-1265
[61]Clahsen PC, van de Velde CJH, Duval C et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. [J] Clin Oncol 1998,16:470-479
[62]Kandioler-Eckersberger D, Ludwig C, Rudas M, et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. [J]Clin Cancer Res 2000,6:50-56
[1]Kaufmann M, von Minckwitz G, Smith R,et al. International expertpanel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations. [J] Clin Oncol 2003,21:2600-2608
[2]Smith IE. Preoperative/neoadjuvant medical therapy for early breast cancer. [J]Lancet Oncol 2001,2:561-570
[3]Fisher B, Bryam J, Wolmark N, et al. Effect Of preoperative chemotherapy on the outcome of women with operable breast cancer, [J] Clin Oncol 1998,16:2672-2685
[4]吕新生,乳腺癌的新辅助化疗,[J]中国普通外科杂志,2006,15(10)：721-724
[5]Chuthapisith S,Eremin JM,et al. Neoadjuvant chemotherapy in women with large and locally advanced breast cancer:chemoresistance and prediction of response to drug therapy. [J] Surgeon.2006,4(4):211-219
[6]Jae K. Lee, Charles Coutant, Young-Chul Kim,et al. Prospective Comparison of Clinical and Genomic Multivariate Predictors of Response to Neoadjuvant Chemotherapy in Breast Cancer. [J] Clin Cancer Res 2010,16:711-718
[7]Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. [J] Clin Oncol 1998,16: 2672-2685
[8]李书玲,乳腺肿瘤学[M].北京：科学技术文献出版社,2000：379-433
[9]杨接辉.CTF方案在乳腺癌新辅助化疗近期的疗效观察.[J]中国综合临床,2004,20(7)：629—630
[10]Van der JA, vandevelde cJ, Julien JP, et al. Preoperative chemotheapy in primary operable breaSt cancer:results from the Eumpean Organization for Research and Treatment of cancer trial 10902. [J] clinical,2001,19(22): 4224-4237
[11]Vlastos G, Mirza N Q, Lenert J T,et al. The feasibility of minimally invasive surgery for stage ⅡA, IIB, andⅢA breast carcinoma patients after tumor downstaging with induction chemotherapy. [J]Cancer,2000,88:1417-1424
[12]Newman L A, Buzdar A U, Singletary S E, et al.A prospective trial of preoperative chemotherapy in resectable breast cancer:predictors of breast-conservation therapy feasibility. [J] Ann Surg Oncol,2002,9:228-234
[13]Baslaim M M, Malik A, Sobhi S, et al.Decreased axillary lymph node retrieval in patients after neoadjuvant chemotherapy. [J]Am J Surg,2002,184:299-230
[14]陈伟光,李梅,李艳薇等,多西他赛联合毗柔比星的新辅助化疗方案治疗乳腺癌的临床观察,[J]实用医学杂志,2009,25(10)：1672-1673
[15]Chaffare H, Limongelli S, Pumshotham A D,et al. Neoadjuvant chemotherapyin breast cancer. [J]Br J Surg,2005,92(-):14-23
[16]Trudeau M and Pagani O. Epirubicin in combination with the taxanes. [J]Seminars in oncology 2001,28(12):41-50
[17]Kenneth Villman. A phase Ⅱ study of epirubicin, cisplatin and capecitabine as neoadjuvant chemotherapy in locally advanced or inflammatory breast cancer, [J] European Journal of Cancer.2007,43(7):1153-1160
[18]Bear HD,Anderson S,Smith RE,et al.Sequential preoperative or postoperative docetaxel added to preperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. [J]J Clin Oncol,2006,24:2019-2027
[19]曹茵,张爱玲,不同新辅助化疗方案治疗局部晚期乳腺癌的疗效比较,[J]实用预防医学.2006,13(1)：68-69
[20]Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer:a trial of two doses by 3 hour infusion in patients with disease recurrence after prior therapy with anthracyclines. [J] Natl Cancer Inst 1995,87:1169-1175
[21]Nabholtz JM, Gelmon K, Bontenbal M et al. Multicenter, randomized comparative study of two doses of Paclitaxel in patients with metastatic breast cancer. [J] J Clin Oncol 1996,14:1858-1867
[22]Seidman AD, Barrett S, Hudis C, et al. Three hour Taxol infusion as intitial and as salvage chemotherapy of metastatic breast cancer. [J] Proc Am Soc Clin Oncol 1994,13:A65
[23]Fountzilas G, Athanassiades A, Giannakakis T, et al. A phase Ⅱ study of Paclitaxel in advanced brease cancer resistant to anthracyclines. [J] Eur J Cancer 1996,32:47-51
[24]Chevallier B, Fumoleau P, Kerbrat P et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer:a phase Ⅱ trial of the EORTC-CSG. [J] J Clin Oncol,1995,13:314-322,
[25]Tubiana-Hulin, M Dieras, V Fumoleau, et al. Phase Ⅱ trial combining docetaxel and doxorubicine in the neoadjuvant setting in patients with operable breast carcinoma:final results. [J] Breast Cancer Res. Treat.,2000,64:250-258
[26]Valero V, Esteva FJ, SahinA,et al. Phase Ⅱ trial of neoadjuvant chemotherapy with docetaxel and doxorubicin, surgery, adjuvant CMF, and radiotherapy tamoxifen in locally advanced breast cancer. [J] Breast Cancer Res. Treat.2000,64:253-260
[27]Luporsi, E, Vanlemmens, L, Coudert, B,et al. Six cycles of FEC 100 versus 6 cycles of epirubicin-docetaxel as neoadjuvant chemotherapy in operable breast cancer patients:preliminary results of a randomized Phase Ⅱ trial of Girec S01. Proc. Am. Soc. [J] Clin. Oncol,2000,19:355-362
[28]Wenzel C., Locker G. J, Schmidinger M., et al. Combined analysis of two Phase Ⅱ trials in patients with primary and advanced breast cancer with epidoxorubicin and docetaxel-granulocyte colony stimulating factor. [J] Anticancer Drugs,2002,13:1-8
[29]E. Espinosa, S Morales,et al. Docetaxel and high-dose epirubicin as neodajuvant chemotherapy in locally advanced breast cancer. [J] Cancer chemotherapy and pharmacology.2003,54(6):546-552
[30]胡薇,施俊义,吡柔比星或表柔比星联合紫杉醇新辅助化疗治疗局部晚期乳腺癌的随机对照研究,[J]第二军医大学学报,2010,31(1)：70-73
[31]Honkoop AH,Luykx de Bakker SA,Hoekman K,et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. [J]Oncolo-gist,1999,4:106-111
[32]Harbeck N, Beck T,et al. Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2 Overexpressing Breast Cancer:Results From the TECHNO Trial of the AGO and GBG Study Groups, [J] Clin Oncol. 2011,1; 29(25):3351-3357
[33]Feldman LD, Hortobagyi GN, Buzdar AU, et al. Pathological assessment of response to induction chemotherapy in breast cancer. [J]Cancer Res 2000,46:2578-2581
[34]I F Faneyte, J G Schrama, et al. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome, [J] Br J Cancer. 2003,88(3):406-412
[35]Keune JD, Jeffe DB, et al. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer, [J]Am J Surg.2010,199(4):477-484
[36]Vinnicombe SJ, MacVicar AD, Guy RL, et al. Primary breast cancer: Mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. [J] Radiology 1996,198:333-340
[37]Yeh E, Slanetz P, Kopans SB, et al.Prospective comparing of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. [J]Am J Roentgenol,2005,184:868-877
[38]张斌,张强,赵林等.乳腺癌新辅助化疗疗效的评价及影响因素分析[J]中华肿瘤杂志,2006,28：867-870
[39]Partridge SC, Gibbs JE, Lu Y, et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. [J] AJR Am J Roentgenol.2002,179(5):1193-1199
[40]Belli P, Costantini M, Malaspina C,et al. MRI accuracy in residual disease evaluation in breast cancer patients treated with neoadjuvant chemotherapy. [J]Clin Radiol.2006,61(11):946-953.
[41]Andre F, Mazouni C, Liedtke C, et al. HER2 expression and efficacy of preoperative paclitaxel/FAC chemotherapy in breast cancer. [J] Breast Cancer Res Treat 2008,108:183-90
[42]Buzdar AU, Valero V, Ibrahim NK, et al. Neoadjuvant therapy with paclitaxel followed by 5-FU, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer:an update of the initial randomized study population and data of additional patients treated with the same regimen. [J] Clin Cancer Res 2007,13:228-33
[43]Michiels S, Koscielny S, Hill C, et al. Prediction of cancer outcome with microarrays:a multiple random validation strategy. Lancet 2005,365:488-92
[44]Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiation:Guidelines of the American Society of Clinical Oncology. [J] Clin Oncol,2001,19:1539-1569,
[45]Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcomes of women with operable breast cancer. [J]Clin Oncol 1998,16:2672-2685
[46]Whelan TJ, Julian J, Wright J, et al. Does local-regional radiation therapy improve survival in breast cancer? A meta-analysis. [J] Clin Oncol 2000,18: 1220-1229
[47]De Steene JV, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival:The missing link. [J] Radiother Oncol 2000,55:263-272
[48]Harris JR, Halpin-Murphy P, McNeese M, et al. Consensus statement on postmastectomy radiation therapy. [J] Int J Radiat Oncol Biol Phys 1999,44: 989-990
[49]Zeina Nahleh, Neoadjuvant chemotherapy for "Triple Negative" breast cancer:a review of current practice and future outlook, Medical Oncology.2001,27, (2):531-539
[50]Cornelia Liedtke, Chafika Mazouni, Kenneth R, et al. Hess, Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer, [J] J Clin Oncol 2008,26(8):1275-1281
[51]Von Minckwitz, G.Kaufmann, M.Kummel,et al, Integrated meta-analysis on 6402 patients with early breast cancer receiving neoadjuvant anthracycline-taxane+/-trastuzumab containing chemotherapy. [C] San Antonio Breast Cancer Symposium, San Antonio,2008,79-83
[52]Carey, L.A., Perou, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. [J] Cancer research,2006,295,2492-2502
[53]Kassam, F., Enright, K., Dent, R., et al.Survival outcomes for patients with metastatic triple-negative breast cancer:implications for clinical practice and trial design. [J] Clin. Breast Cancer.2009.9:29-33
[54]Sikov WM, Dizon DS, Strenger R, et al. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab:a Brown University Oncology Group Study. [J] J Clin Oncol.2009,27:4693-4700
[55]Frasci G, Cornella P, Rinaldo M, et al. Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. [J]Ann Oncol.2009,20:1185-1192.
[56]齐小伟.三阴性乳腺癌患者的新辅助化疗疗效及生存分析.[J]中华乳腺病杂志.2009,3(1)：109-112
[57]Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. [J] Lancet 2003,362:362-369
[58]Hess KR, Anderson K, Symmans WF, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. [J] J Clin Oncol 2006,24: 4236-4244
[59]Macgrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma:Predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST. [J]Br J Cancer, 1996,74:1458-1465
[60]Ogston KN, Miller ID, Schofield AC, et al. Can patients'likelihood of benefiting fromprimary chemotherapy for breast cancer be predicted before commencement of treatment? [J]Breast Cancer Res Treat,2004,86:181-189
[61]Kasami M, Uematsu T, Honda M, et al. Comparison of estrogen receptor, progesterone receptor and Her-2 status in breast cancer pre-and post-neoadjuvant chemotherapy. [J] Breast 2008,17:523-527
[62]Neubauer H, Gall C, Vogel U, et al. Changes in tumour biological markers during primary systemic chemotherapy (PST). [J] Anticancer Res 2008,28: 1797-1804
[63]T Hirata, C Shimizu,et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer, [J] British Journal of Cancer, 2009(101):1529-1536
[64]Jukkola A, Bloigu R, Soini Y, et al.C-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. [J] Eur J Cancer,2001,37(3):347-354
[65]Nigo YI, Yamashita M, Hirahara K, et al. Regulation of allergic airway inflammation through Toll-like receptor 4-mediated modification of mast cell function. [J] Proc Natl Acad Sci USA,2006,103(7):2286-2291
[66]Gregory RK, Pourles TJ, Salter J, et al.Prognoatic relevance of CerbB-2 express following neoadjuvant chemotherapy in patients in a randomized trial of neoadjvant versus adjuvant chemoendocrine therapy. [J] Breast Cancer Res Treat,2000,59(2):171-175
[67]Pritchard KI, Seperherd LE, O'Malley FP, et al. HER2 and Responsiveness of Breast Cancer to Adjuvant Chemotherapy. [J] N England J Med, 2006,354:2103-2014
[68]DiGiovanna MP, Stem DF, Edgenton S,et el. Influence of activation state of ErbB-2(HER-2)on response to adjuvant cyciophesphamide, doxorubiein, and fluoronraeii for stage II, node-positive breast cancer:study 8541 from the Cancer and Leukemia Group B. [J] J Clin Oncol,2008,26(14):2364-2372
[69]林其声,施雄文,徐书楷等,新辅助化疗对乳腺癌ki67、cox-2、p53表达的影响及其临床意义,[J]中国当代医药,2009,16(24)：13-14
[70]Mieog JS, H age JA, V ijuerM J, et a.l Tumouer response to preoperative anthracycline-based chemotherapy in operable breast cancer:the predictive role of p53 express ion. [J] Eur J Cancer,2006,42(10):1369-1379
[71]AnelliA, B ren tan iRR, Gad eha AP,et al. Correlat ion of p53 status with outcome of neoadjuvant chemotherapy using paclitaxel and doxorubicin in stage, breast cancer. [J]Ann Onco,2003,14 (3):428-432
[72]Hagen Blaszyk, Hartmann,, Julie M, et al. A Prospective trial of midwest breast cancer patients:a p53 gene mutation is the most important predictor of adverse outcome. [J] Int. J. Cancer (Pred. Oncol.):2000,89,32-38
[73]Kandioler-Eckersberger D, Ludwig C, Dudas M et al. TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients. [J] Clin Cancer Res 2000,6:50-56
[74]Nishiimura R, Osako T, et al. Clinical significance of Ki-67 in neoadjuvant chemotherapy for primary breast cancer as a predictor for chemosensitivity and for prognosis. [J] Breast Cancer.2010,17(4):269-275
[75]I F Faneyte, J G Schrama, et al. Breast cancer response to neoadjuvant chemotherapy:predictive markers and relation with outcome, [J]Br J Cancer. 2003 Feb 10;88(3):406-412
[76]T Petit, M Witt,et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase Ⅱ alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. [J] European Journal of Cancer, January 2004,40(2):205-211
[77]Gaber J, Richardsm A, Hanis LN, et al. Neoadjuvant cisphain (CDDP) in "triple-negative" breast cancer. [J] Breast Cancer Res Treat,2006,100(1):202